Endeavor

What Are Bispecifics and How Do They Help Patients With Cancer?

A new class of immunotherapy is giving doctors another way to guide the immune system toward hard to treat cancers

Many Lymphoma Patients Missing Out on Best Care

Study shows survival drops when CAR T therapy is not offered to eligible patients

Navigating Survivorship After Bone and Marrow Transplant

Moffitt experts and leukemia survivor share candid insights and support resources

Reaching for the Stars

CAR T therapy transformed one man’s battle with cancer into a story of survival, discovery and impact

Nearly 40 Percent of CAR T Patients Remain in Remission

Many ZUMA-1 participants remain in remission and more than half of those treated remain alive.

New Study Shows CAR T-cell Therapy for Lymphoma Lives up to its Press

Seventeen cancer centers compare real world outcomes of diffuse large B cell lymphoma patients treated with Yescarta® to ZUMA-1 clinical trial data

Father’s Cancer Battle Inspires Son’s Research

Moffitt Physician Co-Led Pivotal Study of CAR-T Therapy

FDA Approves Second CAR T Therapy for Diffuse Large B-Cell Lymphoma

Moffitt Cancer Center is the only center in Florida to offer both FDA approved CAR T therapies, Kymriah™ and Yescarta™